Key Insights
The global Tuberculosis (TB) Diagnostics Market is poised for substantial growth, projected to reach a market size of approximately USD 2.44 billion by 2025. This expansion is driven by a strong Compound Annual Growth Rate (CAGR) of 5.87%, indicating a robust and sustained upward trajectory. The market's development is largely fueled by increasing global efforts to combat TB, including government initiatives, rising healthcare expenditure, and a growing awareness of the disease's impact. Furthermore, advancements in diagnostic technologies, such as the development of rapid, sensitive, and specific molecular tests, are playing a crucial role in early and accurate detection, which is paramount for effective treatment and containment strategies. The demand for these advanced diagnostic tools is expected to outpace traditional methods as healthcare providers prioritize improved patient outcomes and reduced transmission rates.
-Diagnostics-Industry.png)
Tuberculosis (TB) Diagnostics Industry Market Size (In Million)
The market is segmented across various diagnostic test types, with Laboratory Tests and Nucleic Acid Testing anticipated to hold significant shares due to their accuracy and widespread adoption. Radiographic tests, while foundational, are increasingly being complemented by molecular diagnostics. The end-user landscape is dominated by Hospitals/Clinics and Diagnostics/Research Laboratories, reflecting the primary points of patient care and specialized diagnostic services. Geographically, North America and Europe are expected to remain dominant markets, owing to established healthcare infrastructures and high adoption rates of advanced diagnostic technologies. However, the Asia Pacific region, particularly countries like China and India, presents a significant growth opportunity, driven by a high TB burden, increasing investment in healthcare, and the expansion of diagnostic facilities. Restraints, such as the cost of advanced diagnostics and accessibility challenges in low-resource settings, are being addressed by technological innovations aimed at affordability and portability.
-Diagnostics-Industry.png)
Tuberculosis (TB) Diagnostics Industry Company Market Share
Comprehensive Tuberculosis (TB) Diagnostics Market Report: Trends, Growth, and Key Players (2019-2033)
This in-depth report offers a panoramic view of the global Tuberculosis (TB) Diagnostics industry, meticulously analyzing market dynamics, growth trends, and the competitive landscape from 2019 to 2033. With a base year of 2025 and a forecast period extending to 2033, this study provides actionable insights for stakeholders navigating this critical healthcare sector. Leveraging high-traffic keywords such as "TB diagnostics market," "tuberculosis testing," "drug resistance testing," "molecular diagnostics," and "infectious disease diagnostics," this report is optimized for maximum search engine visibility and engagement with industry professionals. We delve into parent and child market segments, offering a granular understanding of market evolution and future potential. All quantitative values are presented in Million units for clarity and ease of analysis.
Tuberculosis (TB) Diagnostics Industry Market Dynamics & Structure
The global Tuberculosis (TB) Diagnostics market is characterized by a moderate to high degree of concentration, driven by the presence of established multinational corporations alongside specialized regional players. Technological innovation is a primary driver, with continuous advancements in molecular diagnostics, such as Nucleic Acid Amplification Tests (NAATs), significantly enhancing sensitivity and specificity, thereby reducing diagnostic turnaround times. Regulatory frameworks, particularly those from agencies like the WHO and national health authorities, play a crucial role in dictating product approval pathways and market access, ensuring the efficacy and safety of diagnostic tools. Competitive product substitutes exist, ranging from traditional smear microscopy to newer rapid molecular assays, creating a dynamic competitive environment where cost-effectiveness and diagnostic accuracy are paramount. End-user demographics, including diverse healthcare settings and varying levels of infrastructure, influence the adoption of different diagnostic technologies. Mergers and acquisitions (M&A) trends indicate a strategic consolidation aimed at expanding product portfolios and market reach, with recent M&A deal volumes indicating significant investment activity. Innovation barriers include the high cost of developing and validating novel diagnostic technologies, as well as the need for robust clinical trials to meet stringent regulatory requirements.
- Market Concentration: Moderate to High, with key players holding substantial market share.
- Technological Innovation: Driven by advancements in molecular diagnostics, point-of-care testing, and AI-assisted interpretation.
- Regulatory Landscape: Stringent regulations by WHO, FDA, EMA, and national bodies influencing market entry and product development.
- Competitive Landscape: Fierce competition between established diagnostics giants and emerging innovative companies.
- End-User Segmentation: Diverse needs across hospitals, clinics, reference laboratories, and low-resource settings.
- M&A Activity: Strategic consolidations to enhance market presence and technology access.
Tuberculosis (TB) Diagnostics Industry Growth Trends & Insights
The Tuberculosis (TB) Diagnostics market is poised for robust growth, driven by increasing global awareness of TB as a significant public health threat and the urgent need for more accurate and rapid diagnostic solutions. The market size evolution reflects a steady upward trajectory, fueled by rising investments in healthcare infrastructure, particularly in high-burden countries. Adoption rates of advanced diagnostic technologies, such as Nucleic Acid Testing (NAT) and drug resistance testing, are accelerating as healthcare providers seek to move beyond traditional, less sensitive methods. Technological disruptions, including the development of multiplex assays capable of detecting multiple pathogens simultaneously and advancements in digital radiography for chest imaging, are transforming the diagnostic landscape. Consumer behavior shifts are evident, with a growing demand for point-of-care diagnostics that can expedite treatment initiation and reduce patient waiting times. The market penetration of sophisticated diagnostic tools is expanding, driven by government initiatives and international aid programs aimed at TB control. The increasing incidence of drug-resistant TB strains (MDR-TB and XDR-TB) further amplifies the demand for specialized diagnostic tests that can identify resistance patterns quickly, allowing for timely and appropriate treatment regimens. This persistent global health challenge, coupled with ongoing research and development efforts, ensures a sustained growth trajectory for the TB diagnostics industry. The global TB diagnostics market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 6.8% from 2025 to 2033, reaching an estimated market value of over $6.5 billion by 2033. This growth is underpinned by significant increases in the volume of laboratory tests performed, expected to reach over 350 million units by 2033, with Nucleic Acid Testing comprising a substantial portion of this volume.
Dominant Regions, Countries, or Segments in Tuberculosis (TB) Diagnostics Industry
The global Tuberculosis (TB) Diagnostics market's dominance is shaped by a confluence of epidemiological burden, healthcare expenditure, and technological adoption rates. Asia-Pacific emerges as the leading region, driven by the high prevalence of TB in countries like India and China, which collectively account for a significant portion of global TB cases. Within this region, India stands out as a pivotal market due to its large population, ongoing efforts to strengthen its public health infrastructure, and substantial investments in TB control programs. The country's commitment to eradicating TB, coupled with increasing access to advanced diagnostic technologies, fuels its market dominance.
- Dominant Region: Asia-Pacific
- Key Countries: India, China, Southeast Asian nations.
- Drivers: High TB incidence, government initiatives for TB elimination, growing healthcare expenditure, and increasing adoption of advanced diagnostics.
- Market Share: Estimated to hold over 40% of the global TB diagnostics market by 2025.
Nucleic Acid Testing (NAT) stands out as the dominant diagnostic test type, experiencing rapid growth due to its superior sensitivity, specificity, and speed compared to traditional methods. Its ability to detect Mycobacterium tuberculosis DNA directly from patient samples, including sputum, blood, and urine, makes it invaluable for both active TB and latent TB diagnosis.
- Dominant Diagnostic Test Type: Nucleic Acid Testing (NAT)
- Key Applications: Diagnosis of active TB, detection of drug-resistant TB, rapid screening.
- Growth Factors: Increasing affordability and accessibility of NAT platforms, regulatory approvals for new NAT assays, and the need for faster turnaround times.
- Market Share: Projected to account for over 55% of the TB diagnostics market revenue by 2025.
Among end-users, Hospitals/Clinics represent the largest segment. This is primarily due to the high volume of patient consultations and diagnostic procedures conducted within these settings, particularly in regions with a high TB burden. The increasing integration of molecular diagnostics into routine clinical practice further solidifies their dominance.
- Dominant End User: Hospitals/Clinics
- Key Features: High patient volume, direct patient care, integration of diagnostic services.
- Growth Factors: Increasing demand for rapid diagnosis and treatment initiation, expansion of point-of-care testing capabilities within clinical settings.
- Market Share: Expected to represent over 60% of the end-user market in 2025.
Tuberculosis (TB) Diagnostics Industry Product Landscape
The Tuberculosis (TB) Diagnostics industry is marked by a diverse and evolving product landscape, driven by relentless innovation to combat this persistent global health challenge. Leading companies are continuously developing advanced diagnostic solutions that offer enhanced sensitivity, specificity, and speed. Nucleic Acid Testing (NAT) platforms, including GeneXpert MTB/RIF Ultra and other molecular assays, are at the forefront, enabling rapid and accurate detection of Mycobacterium tuberculosis and its resistance to key drugs like rifampicin. Radiographic tests, such as digital X-rays and CT scans, remain crucial for initial screening and assessing disease extent, with AI-powered image analysis offering improved diagnostic accuracy. Laboratory tests, encompassing traditional culture methods and serological assays, continue to play a role, particularly in resource-limited settings, although their limitations in speed and accuracy are increasingly being addressed by molecular alternatives. Cytokine detection tests are emerging as promising tools for identifying individuals at high risk of developing active TB or for assessing treatment response. The product landscape is further enriched by the development of point-of-care diagnostic devices, facilitating decentralized testing and immediate patient management.
Key Drivers, Barriers & Challenges in Tuberculosis (TB) Diagnostics Industry
Key Drivers: The Tuberculosis (TB) Diagnostics industry is propelled by several critical drivers. The persistent global burden of TB, including the rise of drug-resistant strains (MDR-TB and XDR-TB), creates an ongoing and urgent demand for effective diagnostic tools. Government initiatives and international funding aimed at TB eradication, such as those by the WHO and national public health agencies, significantly boost market growth through increased procurement and research grants. Technological advancements in molecular diagnostics, rapid testing, and AI-driven analysis are continuously improving diagnostic accuracy and speed, making newer technologies more accessible and attractive. The increasing focus on early and accurate diagnosis to prevent transmission and improve treatment outcomes is a fundamental driver.
Barriers & Challenges: Despite the positive growth trajectory, the industry faces significant barriers and challenges. High upfront costs associated with developing, manufacturing, and validating novel diagnostic technologies can be a substantial hurdle, particularly for smaller companies. Stringent regulatory approval processes can be lengthy and complex, delaying market entry. Limited access to advanced diagnostic infrastructure and skilled personnel in low-resource settings remains a critical challenge, hindering the widespread adoption of sophisticated tests. Supply chain disruptions for essential reagents and consumables can impact the consistent availability of diagnostics. Furthermore, reimbursement policies and pricing pressures from healthcare systems can affect the commercial viability of certain diagnostic products.
Emerging Opportunities in Tuberculosis (TB) Diagnostics Industry
Emerging opportunities within the Tuberculosis (TB) Diagnostics industry lie in the development and deployment of innovative point-of-care (POC) testing solutions. These solutions are crucial for decentralized testing in remote areas and can significantly expedite diagnosis and treatment initiation, thereby curbing transmission. The growing demand for comprehensive drug resistance profiling tests that can identify resistance to multiple drugs simultaneously presents a significant opportunity, driven by the escalating challenge of MDR-TB and XDR-TB. Furthermore, advancements in liquid biopsy techniques for TB diagnosis, potentially enabling non-invasive testing through blood or urine samples, hold immense future potential. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic image analysis for radiographic tests and in interpreting complex molecular data offers avenues for enhanced accuracy and efficiency. Untapped markets in high-burden, underserved regions represent a substantial opportunity for growth, provided that cost-effective and user-friendly diagnostic solutions are developed.
Growth Accelerators in the Tuberculosis (TB) Diagnostics Industry Industry
Several key catalysts are accelerating the growth of the Tuberculosis (TB) Diagnostics industry. Technological breakthroughs in areas like CRISPR-based diagnostics and novel biomarker discovery are paving the way for highly sensitive and specific tests. Strategic partnerships and collaborations between diagnostic manufacturers, research institutions, and global health organizations are crucial for accelerating product development, clinical validation, and market access. Governmental and non-governmental organization (NGO) driven public health campaigns and funding initiatives specifically targeting TB eradication are providing a significant impetus for market expansion. The increasing emphasis on personalized medicine and targeted treatment approaches necessitates the development and widespread adoption of diagnostics that can accurately identify drug resistance profiles and guide therapy. Furthermore, market expansion strategies focused on developing affordable and robust diagnostic solutions tailored for low-resource settings are key accelerators, allowing for broader penetration in high-burden countries.
Key Players Shaping the Tuberculosis (TB) Diagnostics Industry Market
- Becton Dickinson and Company
- Thermo Fisher Scientific Inc
- BioMerieux SA
- AdvaCare Pharma
- Cepheid
- Abbott Laboratories
- Qiagen
- F Hoffmann-La Roche AG
- Hain Lifescience GmbH
- Hologic Corporation
Notable Milestones in Tuberculosis (TB) Diagnostics Industry Sector
- May 2022: The Drug Controller General of India (DCGI) granted market authorization to the Serum Institute, India, for the Cy-Tb kit. This skin test is for individuals 18 years and above and aids in the diagnosis of latent tuberculosis.
- March 2022: SRL Diagnostics launched a whole genome sequencing test for tuberculosis. This innovative test significantly reduces the time required to diagnose multi-drug resistant tuberculosis and provides complete resistance profiling against 18 different TB drugs.
In-Depth Tuberculosis (TB) Diagnostics Industry Market Outlook
The future outlook for the Tuberculosis (TB) Diagnostics industry is highly promising, driven by a persistent global health imperative and continuous innovation. Growth accelerators such as the development of rapid, point-of-care molecular tests, comprehensive drug resistance profiling assays, and AI-integrated diagnostic tools will redefine the diagnostic landscape. Strategic partnerships and increased global health funding will facilitate market penetration in high-burden regions, while a growing emphasis on personalized medicine will drive demand for more precise diagnostic solutions. The industry is poised to witness substantial market expansion as stakeholders focus on developing affordable, accessible, and highly accurate diagnostic technologies to support the global effort to eliminate TB. Future opportunities will also arise from leveraging emerging technologies for early detection and risk stratification of TB infection.
Tuberculosis (TB) Diagnostics Industry Segmentation
-
1. Diagnostic Test Type
- 1.1. Radiographic Test
- 1.2. Laboratory Test
- 1.3. Nucleic Acid Testing
- 1.4. Cytokine Detection Test
- 1.5. Drug Resistance Test
- 1.6. Other Diagnostic Test Types
-
2. End User
- 2.1. Hospital/Clinics
- 2.2. Diagnostics/Research Laboratory
- 2.3. Other End Users
Tuberculosis (TB) Diagnostics Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Middle East
-
5. GCC
- 5.1. South Africa
- 5.2. Rest of Middle East and Africa
-
6. South America
- 6.1. Brazil
- 6.2. Argentina
- 6.3. Rest of South America
-Diagnostics-Industry.png)
Tuberculosis (TB) Diagnostics Industry Regional Market Share
Geographic Coverage of Tuberculosis (TB) Diagnostics Industry
Tuberculosis (TB) Diagnostics Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 5.87% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Burden of Tuberculosis and Multidrug-resistant Tuberculosis (MDR-TB); Increasing R&D Investments and Intensive Product Pipelines; Increasing Government Initiatives and Rising Awareness in the Emerging Markets
- 3.3. Market Restrains
- 3.3.1. High Costs Associated with Tuberculosis Diagnostics; Low Coverage or Absence of Insurance in the Emerging Markets
- 3.4. Market Trends
- 3.4.1. Nucleic Acid Testing Segment Expects to Register a High CAGR During the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 5.1.1. Radiographic Test
- 5.1.2. Laboratory Test
- 5.1.3. Nucleic Acid Testing
- 5.1.4. Cytokine Detection Test
- 5.1.5. Drug Resistance Test
- 5.1.6. Other Diagnostic Test Types
- 5.2. Market Analysis, Insights and Forecast - by End User
- 5.2.1. Hospital/Clinics
- 5.2.2. Diagnostics/Research Laboratory
- 5.2.3. Other End Users
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East
- 5.3.5. GCC
- 5.3.6. South America
- 5.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 6. North America Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 6.1.1. Radiographic Test
- 6.1.2. Laboratory Test
- 6.1.3. Nucleic Acid Testing
- 6.1.4. Cytokine Detection Test
- 6.1.5. Drug Resistance Test
- 6.1.6. Other Diagnostic Test Types
- 6.2. Market Analysis, Insights and Forecast - by End User
- 6.2.1. Hospital/Clinics
- 6.2.2. Diagnostics/Research Laboratory
- 6.2.3. Other End Users
- 6.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 7. Europe Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 7.1.1. Radiographic Test
- 7.1.2. Laboratory Test
- 7.1.3. Nucleic Acid Testing
- 7.1.4. Cytokine Detection Test
- 7.1.5. Drug Resistance Test
- 7.1.6. Other Diagnostic Test Types
- 7.2. Market Analysis, Insights and Forecast - by End User
- 7.2.1. Hospital/Clinics
- 7.2.2. Diagnostics/Research Laboratory
- 7.2.3. Other End Users
- 7.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 8. Asia Pacific Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 8.1.1. Radiographic Test
- 8.1.2. Laboratory Test
- 8.1.3. Nucleic Acid Testing
- 8.1.4. Cytokine Detection Test
- 8.1.5. Drug Resistance Test
- 8.1.6. Other Diagnostic Test Types
- 8.2. Market Analysis, Insights and Forecast - by End User
- 8.2.1. Hospital/Clinics
- 8.2.2. Diagnostics/Research Laboratory
- 8.2.3. Other End Users
- 8.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 9. Middle East Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 9.1.1. Radiographic Test
- 9.1.2. Laboratory Test
- 9.1.3. Nucleic Acid Testing
- 9.1.4. Cytokine Detection Test
- 9.1.5. Drug Resistance Test
- 9.1.6. Other Diagnostic Test Types
- 9.2. Market Analysis, Insights and Forecast - by End User
- 9.2.1. Hospital/Clinics
- 9.2.2. Diagnostics/Research Laboratory
- 9.2.3. Other End Users
- 9.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 10. GCC Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 10.1.1. Radiographic Test
- 10.1.2. Laboratory Test
- 10.1.3. Nucleic Acid Testing
- 10.1.4. Cytokine Detection Test
- 10.1.5. Drug Resistance Test
- 10.1.6. Other Diagnostic Test Types
- 10.2. Market Analysis, Insights and Forecast - by End User
- 10.2.1. Hospital/Clinics
- 10.2.2. Diagnostics/Research Laboratory
- 10.2.3. Other End Users
- 10.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 11. South America Tuberculosis (TB) Diagnostics Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 11.1.1. Radiographic Test
- 11.1.2. Laboratory Test
- 11.1.3. Nucleic Acid Testing
- 11.1.4. Cytokine Detection Test
- 11.1.5. Drug Resistance Test
- 11.1.6. Other Diagnostic Test Types
- 11.2. Market Analysis, Insights and Forecast - by End User
- 11.2.1. Hospital/Clinics
- 11.2.2. Diagnostics/Research Laboratory
- 11.2.3. Other End Users
- 11.1. Market Analysis, Insights and Forecast - by Diagnostic Test Type
- 12. Competitive Analysis
- 12.1. Global Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Becton Dickinson and Company
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 Thermo Fisher Scientific Inc
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 BioMerieux SA
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 AdvaCare Pharma
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 Cepheid
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 Abbott Laboratories
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 Qiagen
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 F Hoffmann-La Roche AG
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.9 Hain Lifescience GmbH
- 12.2.9.1. Overview
- 12.2.9.2. Products
- 12.2.9.3. SWOT Analysis
- 12.2.9.4. Recent Developments
- 12.2.9.5. Financials (Based on Availability)
- 12.2.10 Hologic Corporation
- 12.2.10.1. Overview
- 12.2.10.2. Products
- 12.2.10.3. SWOT Analysis
- 12.2.10.4. Recent Developments
- 12.2.10.5. Financials (Based on Availability)
- 12.2.1 Becton Dickinson and Company
List of Figures
- Figure 1: Global Tuberculosis (TB) Diagnostics Industry Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global Tuberculosis (TB) Diagnostics Industry Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 4: North America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 5: North America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 6: North America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 7: North America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 8: North America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 9: North America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 10: North America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 11: North America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 12: North America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 13: North America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: North America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
- Figure 15: Europe Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 16: Europe Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 17: Europe Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 18: Europe Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 19: Europe Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 20: Europe Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 21: Europe Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 22: Europe Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 23: Europe Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 24: Europe Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 25: Europe Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: Europe Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
- Figure 27: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 28: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 29: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 30: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 31: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 32: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 33: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 34: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 35: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 36: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 37: Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 38: Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
- Figure 39: Middle East Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 40: Middle East Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 41: Middle East Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 42: Middle East Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 43: Middle East Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 44: Middle East Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 45: Middle East Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 46: Middle East Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 47: Middle East Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 48: Middle East Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 49: Middle East Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 50: Middle East Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
- Figure 51: GCC Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 52: GCC Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 53: GCC Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 54: GCC Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 55: GCC Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 56: GCC Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 57: GCC Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 58: GCC Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 59: GCC Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 60: GCC Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 61: GCC Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 62: GCC Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
- Figure 63: South America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Diagnostic Test Type 2025 & 2033
- Figure 64: South America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Diagnostic Test Type 2025 & 2033
- Figure 65: South America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 66: South America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Diagnostic Test Type 2025 & 2033
- Figure 67: South America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by End User 2025 & 2033
- Figure 68: South America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by End User 2025 & 2033
- Figure 69: South America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by End User 2025 & 2033
- Figure 70: South America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by End User 2025 & 2033
- Figure 71: South America Tuberculosis (TB) Diagnostics Industry Revenue (Million), by Country 2025 & 2033
- Figure 72: South America Tuberculosis (TB) Diagnostics Industry Volume (K Unit), by Country 2025 & 2033
- Figure 73: South America Tuberculosis (TB) Diagnostics Industry Revenue Share (%), by Country 2025 & 2033
- Figure 74: South America Tuberculosis (TB) Diagnostics Industry Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 2: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 3: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 4: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 5: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 6: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 7: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 8: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 9: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 10: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 11: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 12: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 13: United States Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 14: United States Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 15: Canada Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 16: Canada Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 17: Mexico Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 18: Mexico Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 20: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 21: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 22: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 23: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 24: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 25: Germany Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Germany Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: United Kingdom Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 28: United Kingdom Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 29: France Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 30: France Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 31: Italy Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 32: Italy Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 33: Spain Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 34: Spain Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 35: Rest of Europe Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 36: Rest of Europe Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 38: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 39: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 40: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 41: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 42: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 43: China Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: China Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Japan Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Japan Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: India Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: India Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Australia Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 50: Australia Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 51: South Korea Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 52: South Korea Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Rest of Asia Pacific Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 54: Rest of Asia Pacific Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 56: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 57: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 58: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 59: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 60: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 61: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 62: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 63: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 64: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 65: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 66: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 67: South Africa Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: South Africa Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: Rest of Middle East and Africa Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: Rest of Middle East and Africa Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Diagnostic Test Type 2020 & 2033
- Table 72: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Diagnostic Test Type 2020 & 2033
- Table 73: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 74: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 75: Global Tuberculosis (TB) Diagnostics Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 76: Global Tuberculosis (TB) Diagnostics Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 77: Brazil Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 78: Brazil Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 79: Argentina Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 80: Argentina Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 81: Rest of South America Tuberculosis (TB) Diagnostics Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 82: Rest of South America Tuberculosis (TB) Diagnostics Industry Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Tuberculosis (TB) Diagnostics Industry?
The projected CAGR is approximately 5.87%.
2. Which companies are prominent players in the Tuberculosis (TB) Diagnostics Industry?
Key companies in the market include Becton Dickinson and Company, Thermo Fisher Scientific Inc , BioMerieux SA, AdvaCare Pharma, Cepheid, Abbott Laboratories, Qiagen, F Hoffmann-La Roche AG, Hain Lifescience GmbH, Hologic Corporation.
3. What are the main segments of the Tuberculosis (TB) Diagnostics Industry?
The market segments include Diagnostic Test Type, End User.
4. Can you provide details about the market size?
The market size is estimated to be USD 2.44 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Burden of Tuberculosis and Multidrug-resistant Tuberculosis (MDR-TB); Increasing R&D Investments and Intensive Product Pipelines; Increasing Government Initiatives and Rising Awareness in the Emerging Markets.
6. What are the notable trends driving market growth?
Nucleic Acid Testing Segment Expects to Register a High CAGR During the Forecast Period.
7. Are there any restraints impacting market growth?
High Costs Associated with Tuberculosis Diagnostics; Low Coverage or Absence of Insurance in the Emerging Markets.
8. Can you provide examples of recent developments in the market?
In May 2022, the Drug Controller General of India (DCGI) granted market authorization to the Serum Institute, India, Cy-Tb kit for 18 years and above that can be used for a skin test for diagnosis of latent tuberculosis.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Tuberculosis (TB) Diagnostics Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Tuberculosis (TB) Diagnostics Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Tuberculosis (TB) Diagnostics Industry?
To stay informed about further developments, trends, and reports in the Tuberculosis (TB) Diagnostics Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence